13,230 PLN (26%)Shortfall: 36,770 PLN
Lung cancer with EGFR mutation❗Paweł is waiting for treatment that is not covered by reimbursement❗
Highlights
Explore the history of
The change in the EGFR gene detected in Paweł, referred to as an insertion in exon 20, is one of the very rare variants of this disease.
In practice, this means that standard treatment methods often prove ineffective, and therapy must be selected with extreme precision, taking into account the specific nature of the cancer itself.
Neurological symptoms were the first sign of the disease.
At first, there were no signs of lung disease. Severe, persistent headaches and a gradual deterioration in his well-being were the first signs that prompted Paweł to seek answers. Further tests triggered a diagnostic process that quickly led to a difficult diagnosis. The test results showed advanced lung cancer with metastases, the development of which is associated with a mutation in the EGFR gene.
The disease changed everyday life
The cancer has already metastasized to his hip bones. For Paweł, this means pain and increasingly limited mobility. Activities that were a natural part of everyday life not so long ago now require enormous effort and determination. On top of that, he suffers from severe headaches, which on some days can completely sap his strength.
Waiting time for treatment
Paweł remains under medical care and is awaiting the next stage of treatment. In the case of EGFR mutation in exon 20, treatment must be selected with extreme precision. Unfortunately , the therapy that offers the best chance of halting the disease in this situation is not currently covered by reimbursement.
This means incurring enormous costs, which are almost impossible for one person to bear.
The illness stopped work
Not long ago, Paweł led an active life and worked professionally. Today, his illness completely prevents him from working. The loss of his source of income means that, in addition to fighting for his health, he also has to deal with the burden of daily obligations that do not disappear despite his illness. The immediate goal is to start therapy that will give Paweł a chance to stop the disease. The cost of treatment exceeds the capabilities of one person, which is why Paweł is now asking for help.
Every bit of support brings him closer to the moment when the most important question for him will not be whether treatment will be possible, but when it can begin.
Promote collection
Donate 1,5% tax
Your e-PIT is the easiest way to settle your taxes. The IRS pre-fills your tax returns, and you can verify, approve or correct them.
- Step 1 - log in to the e-Tax Office and use the e-PIT service.
- Step 2 - in the PIT return form, click on Select an organization.
- Step 3 - in the list of organizations, search for Cancer Fighters Foundation or enter the KRS number 0000581036.
- Step 4 - in the field with the specific goal of 1.5%, indicate the Ward by entering the following data:
Contributions and words of support
1,585.00 PLN(2%)
Still need - 68,415 PLN
The collection was supported by: 8 people
Promote the collection
Download and share materials
Donate 1.5% of your tax
The Foundation's beneficiaries
Set up a piggy bank
Contact us
Download QR code
Moneybox at hand
Lung cancer with EGFR mutation❗Paweł is waiting for treatment that is not covered by reimbursement❗
1,585.00 PLN(2%)
Still need - 68,415 PLN
The collection was supported by: 8 people
Highlights
Explore the history of
The change in the EGFR gene detected in Paweł, referred to as an insertion in exon 20, is one of the very rare variants of this disease.
In practice, this means that standard treatment methods often prove ineffective, and therapy must be selected with extreme precision, taking into account the specific nature of the cancer itself.
Neurological symptoms were the first sign of the disease.
At first, there were no signs of lung disease. Severe, persistent headaches and a gradual deterioration in his well-being were the first signs that prompted Paweł to seek answers. Further tests triggered a diagnostic process that quickly led to a difficult diagnosis. The test results showed advanced lung cancer with metastases, the development of which is associated with a mutation in the EGFR gene.
The disease changed everyday life
The cancer has already metastasized to his hip bones. For Paweł, this means pain and increasingly limited mobility. Activities that were a natural part of everyday life not so long ago now require enormous effort and determination. On top of that, he suffers from severe headaches, which on some days can completely sap his strength.
Waiting time for treatment
Paweł remains under medical care and is awaiting the next stage of treatment. In the case of EGFR mutation in exon 20, treatment must be selected with extreme precision. Unfortunately , the therapy that offers the best chance of halting the disease in this situation is not currently covered by reimbursement.
This means incurring enormous costs, which are almost impossible for one person to bear.
The illness stopped work
Not long ago, Paweł led an active life and worked professionally. Today, his illness completely prevents him from working. The loss of his source of income means that, in addition to fighting for his health, he also has to deal with the burden of daily obligations that do not disappear despite his illness. The immediate goal is to start therapy that will give Paweł a chance to stop the disease. The cost of treatment exceeds the capabilities of one person, which is why Paweł is now asking for help.
Every bit of support brings him closer to the moment when the most important question for him will not be whether treatment will be possible, but when it can begin.
Donate 1.5% of your tax
Your e-PIT is the easiest way to settle your taxes. The IRS pre-fills your tax returns, and you can verify, approve or correct them.
Promote the collection
Contributions and words of support
8,381 PLN (17%)Shortfall: 41,619 PLN
2,240 PLN (3%)Shortfall: 77,760 PLN
PLN 1,720 (6%)Shortfall: PLN 28,280
12,401 PLN (18%)Shortfall: 57,599 PLN
10,662 PLN (15%)Shortfall: 59,338 PLN
3,007 PLN (6%)Shortfall: 46,993 PLN
PLN 1,155 (2%)Shortfall: PLN 68,845
